ArticleMolecular biology of the cell1998
RhoA GTPase and serum response factor control selectively the expression of MyoD without affecting Myf5 in mouse myoblasts.
Article in Molecular biology of the cell, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 122 citations in OpenAlex.
- RhoA Is a Crucial Regulator of Myoblast Fusion.Cells · 2023Article
- Review
- DEPDC1B is a key regulator of myoblast proliferation in mouse and man.Cell proliferation · 2020Article
- Expression profiling of lncRNAs and mRNAs reveals regulation of muscle growth in the Pacific abalone, Haliotis discus hannai.Scientific reports · 2018Article
- Shisa2 regulates the fusion of muscle progenitors.Stem cell research · 2018Article
- Vangl2/RhoA Signaling Pathway Regulates Stem Cell Self-Renewal Programs and Growth in Rhabdomyosarcoma.Cell stem cell · 2018Article
- Srf controls satellite cell fusion through the maintenance of actin architecture.The Journal of cell biology · 2018Article
- Duration of simulated microgravity affects the differentiation of mesenchymal stem cells.Molecular medicine reports · 2017Article
- The STARS signaling pathway: a key regulator of skeletal muscle function.Pflugers Archiv : European journal of physiology · 2014Review
- MyoD-expressing progenitors are essential for skeletal myogenesis and satellite cell development.Developmental biology · 2013Article
- G-protein coupled receptor 56 promotes myoblast fusion through serum response factor- and nuclear factor of activated T-cell-mediated signalling but is not essential for muscle development in vivo.The FEBS journal · 2013Article
- Change in Nox4 expression is accompanied by changes in myogenic marker expression in differentiating C2C12 myoblasts.Pflugers Archiv : European journal of physiology · 2013Article
- Transcriptional profile of GTP-mediated differentiation of C2C12 skeletal muscle cells.Purinergic signalling · 2012Article
- MASTR directs MyoD-dependent satellite cell differentiation during skeletal muscle regeneration.Genes & development · 2012Article
- EphrinA/EphA signal facilitates insulin-like growth factor-I-induced myogenic differentiation through suppression of the Ras/extracellular signal-regulated kinase 1/2 cascade in myoblast cell lines.Molecular biology of the cell · 2011Article
- Regulation of promyogenic signal transduction by cell-cell contact and adhesion.Experimental cell research · 2010Review
- N-cadherin ligation, but not Sonic hedgehog binding, initiates Cdo-dependent p38alpha/beta MAPK signaling in skeletal myoblasts.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- The origin, molecular regulation and therapeutic potential of myogenic stem cell populations.Journal of anatomy · 2009Review
- The small chromatin-binding protein p8 coordinates the association of anti-proliferative and pro-myogenic proteins at the myogenin promoter.Journal of cell science · 2009Article
- The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.Molecular and cellular biology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MyoD and Myf5 belong to the family of basic helix-loop-helix transcription factors that are key operators in skeletal muscle differentiation. MyoD and Myf5 genes are selectively activated during development in a time and region-specific manner and in response to different stimuli. However, molecules that specifically regulate the expression of these two genes and the pathways involved remain to be determined. We have recently shown that the serum response factor (SRF), a transcription factor involved in activation of both mitogenic response and muscle differentiation, is required for MyoD gene expression. We have investigated here whether SRF is also involved in the control of Myf5 gene expression, and the potential role of upstream regulators of SRF activity, the Rho family G-proteins including Rho, Rac, and CDC42, in the regulation of MyoD and Myf5. We show that inactivation of SRF does not alter Myf5 gene expression, whereas it causes a rapid extinction of MyoD gene expression. Furthermore, we show that RhoA, but not Rac or CDC42, is also required for the expression of MyoD. Indeed, blocking the activity of G-proteins using the general inhibitor lovastatin, or more specific antagonists of Rho proteins such as C3-transferase or dominant negative RhoA protein, resulted in a dramatic decrease of MyoD protein levels and promoter activity without any effects on Myf5 expression. We further show that RhoA-dependent transcriptional activation required functional SRF in C2 muscle cells. These data illustrate that MyoD and Myf5 are regulated by different upstream activation pathways in which MyoD expression is specifically modulated by a RhoA/SRF signaling cascade. In addition, our results establish the first link between RhoA protein activity and the expression of a key muscle regulator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.